These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 18608215

  • 1. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [Abstract] [Full Text] [Related]

  • 2. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 4. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.
    BMC Cancer; 2008 Oct 23; 8():307. PubMed ID: 18947390
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS.
    Cancer; 2004 Feb 01; 100(3):499-506. PubMed ID: 14745865
    [Abstract] [Full Text] [Related]

  • 6. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
    Skasko E, Paszko Z, Mazur S.
    Neoplasma; 2005 Feb 01; 52(1):10-7. PubMed ID: 15739020
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 8. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK.
    Clin Cancer Res; 1998 Jan 04; 4(1):7-12. PubMed ID: 9516946
    [Abstract] [Full Text] [Related]

  • 9. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J.
    Eur J Clin Invest; 2008 Jun 04; 38(6):438-46. PubMed ID: 18452545
    [Abstract] [Full Text] [Related]

  • 10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Jun 04; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 11. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK.
    Anticancer Res; 1997 Jun 04; 17(2B):1417-23. PubMed ID: 9137508
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM.
    J Clin Oncol; 2006 Mar 01; 24(7):1037-44. PubMed ID: 16505422
    [Abstract] [Full Text] [Related]

  • 14. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
    Kim JH, Bossuyt V, Ponn T, Lannin D, Haffty BG.
    Clin Cancer Res; 2005 Jul 15; 11(14):5199-205. PubMed ID: 16033837
    [Abstract] [Full Text] [Related]

  • 15. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.
    Clin Cancer Res; 2004 Sep 01; 10(17):5670-6. PubMed ID: 15355892
    [Abstract] [Full Text] [Related]

  • 18. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, Glück S.
    Bone Marrow Transplant; 1999 Aug 01; 24(4):377-84. PubMed ID: 10467326
    [Abstract] [Full Text] [Related]

  • 19. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL.
    J Clin Oncol; 2007 Jul 20; 25(21):3007-14. PubMed ID: 17634479
    [Abstract] [Full Text] [Related]

  • 20. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1419-26. PubMed ID: 18285604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.